{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.68","upperLimit":"32.66","value":"32.66"},{"comment":"N/A = data could not be analyzed at later time points due to the low number of patients.","groupId":"OG001","lowerLimit":"12.48","upperLimit":"NA","value":"21.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"285"}],"units":"Participants"}],"description":"Time to deterioration of ECOG performance status score was summarized at time of assessment. ECOG (Eastern Cooperative Oncology Group)performance scale is a standard criteria for measuring how treatment of cancer impacts their level of functioning in terms of their ability to care for themselves, daily activity, \\& physical ability (walking, working, etc.). Scale score ranges from 0 to 5, 5 being the worst. ECOG scale index: 0 - Fully active, able to carry on all pre-disease performance without restriction. 1 - Restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature, e.g., light housework, office work. 2 - Ambulatory \\& capable of all self-care but unable to carry out any work activities. Up \\& about more than 50% of waking hours. 3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG000","title":"Everolimus + Vinorelbine + Trastuzumab"},{"description":"Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG001","title":"Placebo + Vinorelbine + Trastuzumab"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients.","reportingStatus":"POSTED","timeFrame":"baseline, until disease progression or death up to about 41 months","title":"Median Time to Deterioration of the ECOG Performance Status Score","type":"SECONDARY","unitOfMeasure":"months"}